Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

Weight loss drugs like Ozempic and wegovy have become global sensation ... 5mg weekly lost 16.1 kg (35.5 lb) on average after 72 weeks. For Zepbound’s 10mg weekly dose, the average weight ...

Colorado plans to start limiting insurance coverage of prescription weight-loss drugs for its roughly 40,000 state employees, a cost-cutting measure in a difficult budget year that officials say will ...

The late-stage trial of semaglutide, which it markets as Wegovy to treat obesity ... But the trial showed it achieved an average of 22.7% weight loss after more than a year's treatment, roughly ...